Julian Buchrieser

Julian Buchrieser

Auto-generated profile, based on publicly available information

Julian Buchrieser

Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DPDelphine Planas
Delphine Planas
TBTimothée Bruel
Timothée Bruel
LGLudivine Grzelak
Ludivine Grzelak
FGFlorence Guivel-Benhassine
Florence Guivel-Benhassine
ISIsabelle Staropoli
Isabelle Staropoli
OSOlivier Schwartz
Olivier Schwartz

1 June 2017 in Stem Cell Reports
Verified
Journal Article
Open access
WHWalther Haenseler
Walther Haenseler
SSStephen N. Sansom
Stephen N. Sansom
JBJulian Buchrieser
Julian Buchrieser
SNSarah E. Newey
Sarah E. Newey
CMCraig S. Moore
Craig S. Moore
SCSally Cowley
Sally Cowley
Microglia are increasingly implicated in brain pathology, particularly neurodegenerative disease, with many genes implicated in Alzheimer's, Parkinson's, and motor neuron disease expressed in microglia. There is, therefore, a need for authentic, efficient in vitro models to study human microglial pathological mechanisms. Microglia originate from the yolk sac as MYB-independent macrophages, migrating into the developing brain to complete differentiation. Here, we recapitulate microglial ontogeny by highly efficient differentiation of embryonic MYB-independent iPSC-derived macrophages then co-culture them with iPSC-derived cortical neurons. Co-cultures retain neuronal maturity and functionality for many weeks. Co-culture microglia express key microglia-specific markers and neurodegenerative disease-relevant genes, develop highly dynamic ramifications, and are phagocytic. Upon activation they become more ameboid, releasing multiple microglia-relevant cytokines. Importantly, co-culture microglia downregulate pathogen-response pathways, upregulate homeostatic function pathways, and promote a more anti-inflammatory and pro-remodeling cytokine response than corresponding monocultures, demonstrating that co-cultures are preferable for modeling authentic microglial physiology.

4 November 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JBJulian Buchrieser
Julian Buchrieser
JDJérémy Dufloo
Jérémy Dufloo
MHMathieu Hubert
Mathieu Hubert
BMBlandine Monel
Blandine Monel
DPDelphine Planas
Delphine Planas
OSOlivier Schwartz
Olivier Schwartz
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

25 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
EBEmeline Bonsergent
Emeline Bonsergent
EGEleonora Grisard
Eleonora Grisard
JBJulian Buchrieser
Julian Buchrieser
OSOlivier Schwartz
Olivier Schwartz
CTClotilde Théry
Clotilde Théry
GLGregory Lavieu
Gregory Lavieu
Extracellular vesicles (EVs), including exosomes, are thought to mediate intercellular communication through the transfer of cargoes from donor to acceptor cells. Occurrence of EV-content delivery within acceptor cells has not been unambiguously demonstrated, let alone quantified, and remains debated. Here, we developed a cell-based assay in which EVs containing luciferase- or fluorescent-protein tagged cytosolic cargoes are loaded on unlabeled acceptor cells. Results from dose-responses, kinetics, and temperature-block experiments suggest that EV uptake is a low yield process (~1% spontaneous rate at 1 h). Further characterization of this limited EV uptake, through fractionation of membranes and cytosol, revealed cytosolic release (~30% of the uptaken EVs) in acceptor cells. This release is inhibited by bafilomycin A1 and overexpression of IFITM proteins, which prevent virus entry and fusion. Our results show that EV content release requires endosomal acidification and suggest the involvement of membrane fusion.

13 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DPDelphine Planas
Delphine Planas
ISIsabelle Staropoli
Isabelle Staropoli
VMVincent Michel
Vincent Michel
FLFrédéric Lemoine
Frédéric Lemoine
FDFlora Donati
Flora Donati
OSOlivier Schwartz
Olivier Schwartz
The unceasing circulation of SARS-CoV-2 leads to the continuous emergence of novel viral sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 and JN.1 variants, representing >80% of circulating variants in January 2024. The XBB subvariants carry few but recurrent mutations in the spike, whereas BA.2.86.1 and JN.1 harbor >30 additional changes. These variants replicate in IGROV-1 but no longer in Vero E6 and are not markedly fusogenic. They potently infect nasal epithelial cells, with EG.5.1.3 exhibiting the highest fitness. Antivirals remain active. Neutralizing antibody (NAb) responses from vaccinees and BA.1/BA.2-infected individuals are markedly lower compared to BA.1, without major differences between variants. An XBB breakthrough infection enhances NAb responses against both XBB and BA.2.86 variants. JN.1 displays lower affinity to ACE2 and higher immune evasion properties compared to BA.2.86.1. Thus, while distinct, the evolutionary trajectory of these variants combines increased fitness and antibody evasion.

2 September 2020 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
LGLudivine Grzelak
Ludivine Grzelak
STSarah Temmam
Sarah Temmam
CPCyril Planchais
Cyril Planchais
CDCaroline Demeret
Caroline Demeret
LTLaura Tondeur
Laura Tondeur
SWSylvie van der Werf
Sylvie van der Werf
Different serological assays measuring anti–SARS-CoV-2 antibodies and their neutralizing activity in samples from individuals with severe and mild COVID-19 are compared.